Hubbry Logo
Oral candidiasisOral candidiasisMain
Open search
Oral candidiasis
Community hub
Oral candidiasis
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Oral candidiasis
Oral candidiasis
from Wikipedia
Oral candidiasis
Other namesoral candidosis, oral thrush,[1] oropharyngeal candidiasis, moniliasis,[2] candidal stomatitis, muguet
Oral candidiasis patient showing characteristic white slough on the tongue.
SpecialtyInfectious disease, dentistry, dermatology

Oral candidiasis (Acute pseudomembranous candidiasis), also known among other names as oral thrush,[1] is candidiasis that occurs in the mouth. That is, oral candidiasis is a mycosis (yeast/fungal infection) of Candida species on the mucous membranes of the mouth.

Candida albicans is the most commonly implicated organism in this condition. C. albicans is carried in the mouths of about 50% of the world's population as a normal component of the oral microbiota.[3] This candidal carriage state is not considered a disease, but when Candida species become pathogenic and invade host tissues, oral candidiasis can occur. This change usually constitutes an opportunistic infection by normally harmless micro-organisms because of local (i.e., mucosal) or systemic factors altering host immunity.

Classification

[edit]
Traditional classification of oral candidiasis.[2]
  • Acute candidiasis:
    • pseudomembranous candidiasis (oral thrush)
    • atrophic candidiasis
  • Chronic candidiasis:
    • atrophic candidiasis
    • hyperplastic candidiasis
      • chronic oral candidiasis (Candida leukoplakia)
      • candidiasis endocrinopathy syndrome
      • chronic localized mucocutaneous candidiasis
      • chronic diffuse candidiasis.

Classification of oral candidiasis.[2]
  • Primary oral candidiasis (group I)
    • Pseudomembranous (acute or chronic)
    • Erythematous (acute or chronic)
    • Hyperplastic: plaque-like, nodular
    • Candida-associated lesions: Denture related stomatitis, angular stomatitis, median rhomboid glossitis, linear gingival erythema
  • Secondary oral candidiasis (group II)
    • Oral manifestations of systemic mucocutaneous candidiasis (due to diseases such as thymic aplasia and candidiasis endocrinopathy syndrome)

Oral candidiasis is a mycosis (fungal infection). Traditionally, oral candidiasis is classified using the Lehner system, originally described in the 1960s, into acute and chronic forms (see table). Some of the subtypes almost always occur as acute (e.g., acute pseudomembranous candidiasis), and others chronic. However, these typical presentations do not always hold true, which created problems with this system. A more recently proposed classification of oral candidiasis distinguishes primary oral candidiasis, where the condition is confined to the mouth and perioral tissues, and secondary oral candidiasis, where there is involvement of other parts of the body in addition to the mouth. The global human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pandemic has been an important factor in the move away from the traditional classification since it has led to the formation of a new group of patients who present with atypical forms of oral candidiasis.[2]

By appearance

[edit]

Three main clinical appearances of candidiasis are generally recognized: pseudomembranous, erythematous (atrophic) and hyperplastic.[4] Most often, affected individuals display one clear type or another, but sometimes there can be more than one clinical variant in the same person.[5]

Pseudomembranous candidiasis in the mouth and oropharynx.
Pseudomembranous candidiasis in a person with HIV

Pseudomembranous

[edit]

Acute pseudomembranous candidiasis is a classic form of oral candidiasis,[6] commonly referred to as thrush.[4] Overall, this is the most common type of oral candidiasis,[7] accounting for about 35% of oral candidiasis cases.[8]

It is characterized by a coating or individual patches of pseudomembranous white slough that can be easily wiped away to reveal erythematous (reddened), and sometimes minimally bleeding, mucosa beneath.[7] These areas of pseudomembrane are sometimes described as "curdled milk",[4] or "cottage cheese".[7] The white material is made up of debris, fibrin, and desquamated epithelium that has been invaded by yeast cells and hyphae that invade to the depth of the stratum spinosum.[4] As an erythematous surface is revealed beneath the pseudomembranes, some consider pseudomembranous candidiasis and erythematous candidiasis stages of the same entity.[4] Some sources state that if there is bleeding when the pseudomembrane is removed, then the mucosa has likely been affected by an underlying process such as lichen planus or chemotherapy.[5] Pseudomembraneous candidiasis can involve any part of the mouth, but usually it appears on the tongue, buccal mucosae or palate.[7]

It is classically an acute condition, appearing in infants, people taking antibiotics or immunosuppressant medications, or immunocompromising diseases.[6] However, sometimes it can be chronic and intermittent, even lasting for many years. Chronicity of this subtype generally occurs in immunocompromised states, (e.g., leukemia, HIV) or in persons who use corticosteroids topically or by aerosol.[4] Acute and chronic pseudomembranous candidiasis are indistinguishable in appearance.[6]

Erythematous

[edit]

Erythematous (atrophic) candidiasis is when the condition appears as a red, raw-looking lesion.[8] Some sources consider denture-related stomatitis, angular stomatitis, median rhomboid glossitis, and antibiotic-induced stomatitis as subtypes of erythematous candidiasis, since these lesions are commonly erythematous/atrophic. It may precede the formation of a pseudomembrane, be left when the membrane is removed, or arise without prior pseudomembranes.[6] Some sources state that erythematous candidiasis accounts for 60% of oral candidiasis cases.[8] Where it is associated with inhalation steroids (often used for treatment of asthma), erythematous candidiasis commonly appears on the palate or the dorsum of the tongue.[6] On the tongue, there is loss of the lingual papillae (depapillation), leaving a smooth area.[5]

Acute erythematous candidiasis usually occurs on the dorsum of the tongue in persons taking long term corticosteroids or antibiotics, but occasionally it can occur after only a few days of using a topical antibiotic.[9] This is usually termed "antibiotic sore mouth", "antibiotic sore tongue",[9] or "antibiotic-induced stomatitis" because it is commonly painful as well as red.

Chronic erythematous candidiasis is more usually associated with denture wearing (see denture-related stomatitis).[citation needed]

Hyperplastic

[edit]

This variant is also sometimes termed "plaque-like candidiasis" or "nodular candidiasis".[6] The most common appearance of hyperplastic candidiasis is a persistent white plaque that does not rub off. The lesion may be rough or nodular in texture.[10] Hyperplastic candidiasis is uncommon, accounting for about 5% of oral candidiasis cases,[8] and is usually chronic and found in adults. The most common site of involvement is the commissural region of the buccal mucosa, usually on both sides of the mouth.[10]

Another term for hyperplastic candidiasis is "candidal leukoplakia". This term is a largely historical synonym for this subtype of candidiasis, rather than a true leukoplakia.[11] Indeed, it can be clinically indistinguishable from true leukoplakia, but tissue biopsy shows candidal hyphae invading the epithelium. Some sources use this term to describe leukoplakia lesions that become colonized secondarily by Candida species, thereby distinguishing it from hyperplastic candidiasis.[10] It is known that Candida resides more readily in mucosa that is altered, such as may occur with dysplasia and hyperkeratosis in an area of leukoplakia.[citation needed]

Associated lesions

[edit]

Candida-associated lesions are primary oral candidiases (confined to the mouth), where the causes are thought to be multiple.[4] For example, bacteria as well as Candida species may be involved in these lesions.[6] Frequently, antifungal therapy alone does not permanently resolve these lesions, but rather the underlying predisposing factors must be addressed, in addition to treating the candidiasis.[4]

Angular cheilitis

[edit]
Angular cheilitis

Angular cheilitis is inflammation at the corners (angles) of the mouth, very commonly involving Candida species, when sometimes the terms "Candida-associated angular cheilitis",[9] or less commonly "monilial perlèche" are used.[12] Candida organisms alone are responsible for about 20% of cases,[5] and a mixed infection of C. albicans and Staphylococcus aureus for about 60% of cases.[3] Signs and symptoms include soreness, erythema (redness), and fissuring of one, or more commonly both the angles of the mouth, with edema (swelling) seen intraorally on the commissures (inside the corners of the mouth). Angular cheilitis generally occurs in elderly people and is associated with denture related stomatitis.[13]

[edit]

This term refers to a mild inflammation and erythema of the mucosa beneath a denture, usually an upper denture in elderly edentulous individuals (with no natural teeth remaining). Some report that up to 65% of denture wearers have this condition to some degree.[14] About 90% of cases are associated with Candida species,[13] where sometimes the terms "Candida-associated denture stomatitis",[14] or "Candida-associated denture-induced stomatitis" (CADIS),[15] are used. Some sources state that this is by far the most common form of oral candidiasis.[15] Although this condition is also known as "denture sore mouth",[5] there is rarely any pain.[15] Candida is associated with about 90% of cases of denture related stomatitis.[2]

Median rhomboid glossitis

[edit]
Median rhomboid glossitis

This is an elliptical or rhomboid lesion in the center of the dorsal tongue, just anterior (in front) of the circumvallate papillae. The area is depapillated, reddened (or red and white) and rarely painful. There is frequently Candida species in the lesion, sometimes mixed with bacteria.[13]

Linear gingival erythema

[edit]

This is a localized or generalized, linear band of erythematous gingivitis (inflammation of the gums). It was first observed in HIV infected individuals and termed "HIV-gingivitis", but the condition is not confined to this group.[4] Candida species are involved, and in some cases the lesion responds to antifungal therapy, but it is thought that other factors exist, such as oral hygiene and human herpesviruses. This condition can develop into necrotizing ulcerative periodontitis.[16]

Others

[edit]

Chronic multifocal oral candidiasis

[edit]

This is an uncommon form of chronic (more than one month in duration) candidal infection involving multiple areas in the mouth, without signs of candidiasis on other mucosal or cutaneous sites. The lesions are variably red and/or white. Unusually for candidal infections, there is an absence of predisposing factors such as immunosuppression, and it occurs in apparently healthy individuals, normally elderly males. Smoking is a known risk factor.[13]

Chronic mucocutaneous candidiasis

[edit]

This refers to a group of rare syndromes characterized by chronic candidal lesions on the skin, in the mouth and on other mucous membranes (i.e., a secondary oral candidiasis). These include Localized chronic mucocutaneous candidiasis, diffuse mucocutaneous candidiasis (Candida granuloma), candidiasis–endocrinopathy syndrome and candidiasis thymoma syndrome. About 90% of people with chronic mucocutaneous candidiasis have candidiasis in the mouth.[6]

Signs and symptoms

[edit]

Signs and symptoms are dependent upon the type of oral candidiasis. Often, apart from the appearance of the lesions, there are usually no other signs or symptoms. Most types of oral candidiasis are painless, but a burning sensation may occur in some cases.[8] Candidiasis can, therefore, sometimes be misdiagnosed as burning mouth syndrome. A burning sensation is more likely with erythematous (atrophic) candidiasis, whilst hyperplastic candidiasis is normally entirely asymptomatic.[5] Acute atrophic candidiasis may feel like the mouth has been scalded with a hot liquid.[5] Another potential symptom is a metallic, acidic, salty or bitter taste in the mouth.[5][8] The pseudomembranous type rarely causes any symptoms apart from possibly some discomfort or bad taste due to the presence of the membranes.[5][6] Sometimes the patient describes the raised pseudomembranes as "blisters."[5] Occasionally there can be dysphagia (difficulty swallowing), which indicates that the candidiasis involves the oropharynx or the esophagus,[7] as well as the mouth. The trachea and the larynx may also be involved where there is oral candidiasis, and this may cause hoarseness of the voice.[15]

Causes

[edit]

Species

[edit]

The causative organism is usually Candida albicans,[5] or less commonly other Candida species such as (in decreasing order of frequency) Candida tropicalis,[17] Candida glabrata,[17] Candida parapsilosis,[17] Candida krusei,[17] or other species (Candida stellatoidea,[17] Candida pseudotropicalis,[17] Candida famata,[17] Candida rugosa,[17] Candida geotrichium,[13] Candida dubliniensis,[13] and Candida guilliermondii).[17] C. albicans accounts for about 50% of oral candidiasis cases,[18] and together C. albicans, C. tropicalis and C. glabrata account for over 80% of cases.[6] Candidiasis caused by non-C. albicans Candida (NCAC) species is associated more with immunodeficiency.[13] For example, in HIV/AIDS, C. dubliniensis and C. geotrichium can become pathogenic.[13]

About 35-50% of humans possess C. albicans as part of their normal oral microbiota.[5] With more sensitive detection techniques, this figure is reported to rise to 90%.[6] This candidal carrier state is not considered a disease, since there are no lesions or symptoms of any kind. Oral carriage of Candida is pre-requisite for the development of oral candidiasis. For Candida species to colonize and survive as a normal component of the oral microbiota, the organisms must be capable of adhering to the epithelial surface of the mucous membrane lining the mouth.[19] This adhesion involves adhesins (e.g., hyphal wall protein 1), and extracellular polymeric materials (e.g., mannoprotein).[13] Therefore, strains of Candida with more adhesion capability have more pathogenic potential than other strains.[6] The prevalence of Candida carriage varies with geographic location,[6] and many other factors. Higher carriage is reported during the summer months,[6] in females,[6] in hospitalized individuals,[6] in persons with blood group O and in non-secretors of blood group antigens in saliva.[6] Increased rates of Candida carriage are also found in people who eat a diet high in carbohydrates, people who wear dentures, people with xerostomia (dry mouth), in people taking broad spectrum antibiotics, smokers, and in immunocompromised individuals (e.g., due to HIV/AIDS, diabetes, cancer, Down syndrome or malnutrition).[13] Age also influences oral carriage, with the lowest levels occurring in newborns, increasing dramatically in infants, and then decreasing again in adults. Investigations have quantified oral carriage of Candida albicans at 300-500 colony forming units in healthy persons.[20] More Candida is detected in the early morning and the late afternoon. The greatest quantity of Candida species are harbored on the posterior dorsal tongue,[13] followed by the palatal and the buccal mucosae.[20] Mucosa covered by an oral appliance such as a denture harbors significantly more candida species than uncovered mucosa.[20]

When Candida species cause lesions - the result of invasion of the host tissues - this is termed candidiasis.[2][19] Some consider oral candidiasis a change in the normal oral environment rather than an exposure or true "infection" as such.[7] The exact process by which Candida species switch from acting as normal oral commensals (saprophytic) state in the carrier to acting as a pathogenic organism (parasitic state) is not completely understood.[6]

Several Candida species are polymorphogenic,[18] that is, capable of growing in different forms depending on the environmental conditions. C. albicans can appear as a yeast form (blastospores), which is thought to be relatively harmless; and a hyphal form associated with invasion of host tissues.[5] Apart from true hyphae, Candida can also form pseudohyphae — elongated filamentous cells, lined end to end.[4] As a general rule, candidiasis presenting with white lesions is mainly caused by Candida species in the hyphal form and red lesions by yeast forms.[13] C. albicans and C. dubliniensis are also capable of forming germ tubes (incipient hyphae) and chlamydospores under the right conditions. C. albicans is categorized serologically into A or B serotypes. The prevalence is roughly equal in healthy individuals, but type B is more prevalent in immunocompromised individuals.[citation needed]

Predisposing factors

[edit]
Common local and systemic predisposing factors.[18]
Local host factors
Systemic host factors

The host defenses against opportunistic infection of candida species are

  • The oral epithelium, which acts both as a physical barrier preventing micro-organisms from entering the tissues, and is the site of cell mediated immune reactions.
  • Competition and inhibition interactions between candida species and other micro-organisms in the mouth, such as the many hundreds of different kinds of bacteria.
  • Saliva, which possesses both mechanical cleansing action and immunologic action, including salivary immunoglobulin A antibodies, which aggregate candida organisms and prevent them adhering to the epithelial surface; and enzymatic components such as lysozyme, lactoperoxidase and antileukoprotease.[13]

Disruption to any of these local and systemic host defense mechanisms constitutes a potential susceptibility to oral candidiasis, which rarely occurs without predisposing factors.[4] It is often described as being "a disease of the diseased",[2][4] occurring in the very young, the very old, or the very sick.[4][6][21]

Oral candidiasis in an infant. At very young ages, the immune system is yet to develop fully.

Immunodeficiency

[edit]

Immunodeficiency is a state of reduced function of the immune system, which can be caused by medical conditions or treatments.

Acute pseudomembranous candidiasis occurs in about 5% of newborn infants.[9] Candida species are acquired from the mother's vaginal canal during birth. At very young ages, the immune system is yet to develop fully and there is no individual immune response to candida species.[9] An infant's antibodies to the fungus are normally supplied by the mother's breast milk.

Other forms of immunodeficiency which may cause oral candidiasis include HIV/AIDS,[22] active cancer and treatment, chemotherapy or radiotherapy.[3][23]

Corticosteroid medications may contribute to the appearance of oral candidiasis,[24] as they cause suppression of immune function either systemically or on a local/mucosal level, depending on the route of administration. Topically administered corticosteroids in the mouth may take the form of mouthwashes, dissolving lozenges or mucosal gels; sometimes being used to treat various forms of stomatitis. Systemic corticosteroids may also result in candidiasis.

Inhaled corticosteroids (e.g., for treatment of asthma or chronic obstructive pulmonary disease), are not intended to be administered topically in the mouth, but inevitably there is contact with the oral and oropharyngeal mucousa as it is inhaled. In asthmatics treated with inhaled steroids, clinically detectable oral candidiasis may occur in about 5-10% of adults and 1% of children.[25] Where inhaled steroids are the cause, the candidal lesions are usually of the erythematous variety.[6] Candidiasis appears at the sites where the steroid has contacted the mucosa, typically the dorsum of the tongue (median rhomboid glossitis) and sometimes also on the palate.[26][27] Candidal lesions on both sites are sometimes termed "kissing lesions"[26][27] because they approximate when the tongue is in contact with the palate.

Denture wearing

[edit]

Denture wearing and poor denture hygiene, particularly wearing the denture continually rather than removing it during sleep,[3] is another risk factor for both candidal carriage and oral candidiasis. Dentures provide a relative acidic, moist and anaerobic environment because the mucosa covered by the denture is sheltered from oxygen and saliva.[28] Loose, poorly fitting dentures may also cause minor trauma to the mucosa,[4] which is thought to increase the permeability of the mucosa and increase the ability of C. albicans to invade the tissues.[28][29] These conditions all favor the growth of C. albicans. Sometimes dentures become very worn, or they have been constructed to allow insufficient lower facial height (occlusal vertical dimension), leading to over-closure of the mouth (an appearance sometimes described as "collapse of the jaws"). This causes deepening of the skin folds at the corners of the mouth (nasolabial crease), in effect creating intertriginous areas where another form of candidiasis, angular cheilitis, can develop. Candida species are capable of adhering to the surface of dentures, most of which are made from polymethylacrylate. They exploit micro-fissures and cracks in the surface of dentures to aid their retention. Dentures may therefore become covered in a biofilm,[18] and act as reservoirs of infection,[7] continually re-infecting the mucosa. For this reason, disinfecting the denture is a vital part of treatment of oral candidiasis in persons who wear dentures, as well as correcting other factors like inadequate lower facial height and fit of the dentures.

Dry mouth

[edit]

Both the quantity and quality of saliva are important oral defenses against candida.[6] Decreased salivary flow rate or a change in the composition of saliva,[8] collectively termed salivary hypofunction or hyposalivation is an important predisposing factor. Xerostomia is frequently listed as a cause of candidiasis,[3] but xerostomia can be subjective or objective, i.e., a symptom present with or without actual changes in the saliva consistency or flow rate.

Diet

[edit]

Malnutrition,[3] whether by malabsorption,[17] or poor diet, especially hematinic deficiencies (iron, vitamin B12, folic acid) can predispose to oral candidiasis,[6] by causing diminished host defense and epithelial integrity. For example, iron deficiency anemia is thought to cause depressed cell-mediated immunity.[28] Some sources state that deficiencies of vitamin A or pyridoxine are also linked.[17]

There is limited evidence that a diet high in carbohydrates predisposes to oral candidiasis.[9] In vitro and studies show that Candidal growth, adhesion and biofilm formation is enhanced by the presence of carbohydrates such as glucose, galactose and sucrose.[28]

Smoking

[edit]

Smoking, especially heavy smoking, is an important predisposing factor but the reasons for this relationship are unknown. One hypothesis is that cigarette smoke contains nutritional factors for C. albicans, or that local epithelial alterations occur that facilitate colonization of candida species.[28]

Antibiotics

[edit]

Broad-spectrum antibiotics (e.g. tetracycline) eliminate the competing bacteria and disrupt the normally balanced ecology of oral microorganisms,[5][6] which can cause antibiotic-induced candidiasis.[3]

Other factors

[edit]

Several other factors can contribute to infection, including endocrine disorders (e.g. diabetes when poorly controlled),[30] and/or the presence of certain other mucosal lesions, especially those that cause hyperkeratosis and/or dysplasia[4] (e.g. lichen planus). Such changes in the mucosa predispose it to secondary infection with candidiasis.[9][24] Other physical mucosal alterations are sometimes associated with candida overgrowth, such as fissured tongue (rarely),[7] tongue piercing, atopy,[6] and/or hospitalization.[4]

Diagnosis

[edit]

The diagnosis can typically be made from the clinical appearance alone,[7] but not always. As candidiasis can be variable in appearance, and present with white, red or combined white and red lesions, the differential diagnosis can be extensive. In pseudomembraneous candidiasis, the membranous slough can be wiped away to reveal an erythematous surface underneath. This is helpful in distinguishing pseudomembraneous candidiasis from other white lesions in the mouth that cannot be wiped away, such as lichen planus, oral hairy leukoplakia. Erythematous candidiasis can mimic geographic tongue. Erythematous candidiasis usually has a diffuse border that helps distinguish it from erythroplakia, which normally has a sharply defined border.[6]

Special investigations to detect the presence of candida species include oral swabs, oral rinse or oral smears.[31] Smears are collected by gentle scraping of the lesion with a spatula or tongue blade and the resulting debris directly applied to a glass slide. Oral swabs are taken if culture is required. Some recommend that swabs be taken from 3 different oral sites.[3] Oral rinse involves rinsing the mouth with phosphate-buffered saline for 1 minute and then spitting the solution into a vessel that examined in a pathology laboratory. Oral rinse technique can distinguish between commensal candidal carriage and candidiasis. If candidal leukoplakia is suspected, a biopsy may be indicated.[31] Smears and biopsies are usually stained with periodic acid-Schiff, which stains carbohydrates in fungal cell walls in magenta. Gram staining is also used as Candida stains are strongly Gram positive.[24]

Sometimes an underlying medical condition is sought, and this may include blood tests for full blood count and hematinics.

If a biopsy is taken, the histopathologic appearance can be variable depending upon the clinical type of candidiasis. Pseudomembranous candidiasis shows hyperplastic epithelium with a superficial parakeratotic desquamating (i.e., separating) layer.[32] Hyphae penetrate to the depth of the stratum spinosum,[4] and appear as weakly basophilic structures. Polymorphonuclear cells also infiltrate the epithelium, and chronic inflammatory cells infiltrate the lamina propria.[32]

Atrophic candidiasis appears as thin, atrophic epithelium, which is non-keratinized. Hyphae are sparse, and inflammatory cell infiltration of the epithelium and the lamina propria. In essence, atrophic candidiasis appears like pseudomembranous candidiasis without the superficial desquamating layer.[32]

Hyperplastic candidiasis is variable. Usually there is hyperplastic and acanthotic epithelium with parakeratosis. There is an inflammatory cell infiltrate and hyphae are visible. Unlike other forms of candidiasis, hyperplastic candidiasis may show dysplasia.[32]

Treatment

[edit]

Oral candidiasis can be treated with topical anti-fungal drugs, such as nystatin, miconazole, Gentian violet or amphotericin B. Surgical excision of the lesions may be required in cases that do not respond to anti-fungal medications.[33]

Underlying immunosuppression may be medically manageable once it is identified, and this helps prevent recurrence of candidal infections.

Patients who are immunocompromised, either with HIV/AIDS or as a result of chemotherapy, may require systemic prevention or treatment with oral or intravenous administered anti-fungals. However, there is strong evidence that drugs that are absorbed or partially absorbed from the GI tract can prevent candidiasis more effectively than drugs that are not absorbed in the same way.[34]

If candidiasis is secondary to corticosteroid or antibiotic use, then use may be stopped, although this is not always a feasible option. Candidiasis secondary to the use of inhaled steroids may be treated by rinsing out the mouth with water after taking the steroid.[15] Use of a spacer device to reduce the contact with the oral mucosa may greatly reduce the risk of oral candidiasis.[25]

In recurrent oral candidiasis, the use of azole antifungals risks selection and enrichment of drug-resistant strains of candida organisms.[30] Drug resistance is increasingly more common and presents a serious problem in persons who are immunocompromised.[13]

Prophylactic use of antifungals is sometimes employed in persons with HIV disease, during radiotherapy, during immunosuppressive or prolonged antibiotic therapy as the development of candidal infection in these groups may be more serious.[2]

The candidal load in the mouth can be reduced by improving oral hygiene measures, such as regular toothbrushing and use of anti-microbial mouthwashes.[18] Since smoking is associated with many forms of oral candidiasis, cessation may be beneficial.[13]

Denture hygiene

[edit]

Good denture hygiene involves regular cleaning of the dentures, and leaving them out of the mouth during sleep. This gives the mucosa a chance to recover, while wearing a denture during sleep is often likened to sleeping in one's shoes. In oral candidiasis, the dentures may act as a reservoir of Candida species known as denture stomatitis[35][36][37][7] which continually reinfects the mucosa once antifungal medication is stopped. Therefore, they must be disinfected as part of the treatment for oral candidiasis. There are commercial denture cleaner preparations for this purpose, but it is readily accomplished by soaking the denture overnight in a 1:10 solution of sodium hypochlorite (Milton, or household bleach).[7] Bleach may corrode metal components,[13] so if the denture contains metal, soaking it twice daily in chlorhexidine solution can be carried out instead. An alternative method of disinfection is to use a 10% solution of acetic acid (vinegar) as an overnight soak, or to microwave the dentures in 200mL water for 3 minutes at 650 watts.[13] Microwave sterilization is only suitable if no metal components are present in the denture. Antifungal medication can also be applied to the fitting surface of the denture before it is put back in the mouth. Other problems with the dentures, such as inadequate occlusal vertical dimension may also need to be corrected in the case of angular cheilitis.

Prognosis

[edit]

The severity of oral candidiasis is subject to great variability from one person to another and in the same person from one occasion to the next.[8] The prognosis of such infection is usually excellent after the application of topical or systemic treatments. However, oral candidiasis can be recurrent.[8] Individuals continue to be at risk of the condition if underlying factors such as reduced salivary flow rate or immunosuppression are not rectifiable.[8]

Candidiasis can be a marker for underlying disease,[20] so the overall prognosis may also be dependent upon this. For example, a transient erythematous candidiasis that developed after antibiotic therapy usually resolves after antibiotics are stopped (but not always immediately),[15] and therefore carries an excellent prognosis—but candidiasis may occasionally be a sign of more sinister undiagnosed pathology, such as HIV/AIDS or leukemia.

It is possible for candidiasis to spread to/from the mouth, from sites such as the pharynx, esophagus, lungs, liver, anogenital region, skin or the nails.[13] The spread of oral candidiasis to other sites usually occurs in debilitated individuals.[15] It is also possible that candidiasis is spread by sexual contact.[13] Rarely, a superficial candidal infection such as oral candidiasis can cause invasive candidiasis, and even prove fatal. The observation that Candida species are normally harmless commensals on the one hand, but are also occasionally capable of causing fatal invasive candidiases, has led to the description "Dr Jekyll and Mr Hyde".[38]

The role of thrush in the hospital and ventilated patients is not entirely clear, however, there is a theoretical risk of positive interaction of candida with topical bacteria.[39]

Epidemiology

[edit]

In humans, oral candidiasis is the most common form of candidiasis,[17] by far the most common fungal infection of the mouth,[5] and it also represents the most common opportunistic oral infection in humans[40] with lesions only occurring when the environment favors pathogenic behavior.

Oropharyngeal candidiasis is common during cancer care,[23] and it is a very common oral sign in individuals with HIV.[22] Oral candidiasis occurs in about two thirds of people with concomitant AIDS and esophageal candidiasis.[41]

The incidence of all forms of candidiasis have increased in recent decades. This is due to developments in medicine, with more invasive medical procedures and surgeries, more widespread use of broad spectrum antibiotics and immunosuppression therapies. The HIV/AIDs global pandemic has been the greatest factor in the increased incidence of oral candidiasis since the 1980s. The incidence of candidiasis caused by NCAC species is also increasing, again thought to be due to changes in medical practise (e.g., organ transplantation and use of indwelling catheters).[18]

History

[edit]

Oral candidiasis has been recognized throughout recorded history.[18] The first description of this condition is thought to have occurred in the 4th century B.C. in "Epidemics" (a treatise that is part of the hippocratic corpus), where descriptions of what sounds like oral candidiasis are stated to occur with severe underlying disease.[20][42]

The colloquial term "thrush" is of unknown origin but may stem from an unrecorded Old English word *þrusc or from a Scandinavian root. The term is not related to the bird of the same name.[43]

Society and culture

[edit]

Many pseudoscientific claims by proponents of alternative medicine surround the topic of candidiasis. Oral candidiasis is sometimes presented in this manner as a symptom of a widely prevalent systemic candidiasis, candida hypersensitivity syndrome, yeast allergy, or gastrointestinal candida overgrowth, which are medically unrecognized conditions. [citation needed](See: Alternative medicine in Candidiasis)

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Oral candidiasis, also known as oral thrush, is an opportunistic fungal infection of the oral mucosa caused by an overgrowth of yeast from the genus Candida, most commonly Candida albicans. This condition typically arises when the normal balance of microorganisms in the mouth is disrupted, leading to the formation of characteristic white, plaque-like lesions that can be scraped off to reveal erythematous tissue underneath. It affects the tongue, inner cheeks, gums, tonsils, or roof of the mouth and is particularly common in vulnerable populations such as infants, older adults, and individuals with weakened immune systems. The primary risk factors for oral candidiasis include immunosuppression from conditions like , cancer treatments such as or , and chronic use of corticosteroids or broad-spectrum antibiotics that alter oral flora. Other contributing factors encompass diabetes mellitus due to elevated salivary glucose levels, ill-fitting promoting microbial adhesion, and extremes of age where salivary defenses are reduced. Epidemiologically, it occurs in over 90% of people with and is equally prevalent in males and females, with higher incidence in neonates around the fourth week of life. Clinically, oral candidiasis presents in several forms, including pseudomembranous thrush with removable white patches, erythematous or atrophic variants causing soreness and burning, and hyperplastic types with adherent white plaques often linked to use. Common symptoms involve painless or painful white lesions, oral discomfort, altered taste, and in severe cases, difficulty swallowing or secondary bacterial infection. is typically clinical based on appearance and history, though microscopic examination or culture may confirm Candida species in recurrent or atypical cases. Treatment primarily involves antifungal therapies, with topical agents like nystatin suspension or clotrimazole lozenges for mild, uncomplicated infections, administered for 7-14 days to ensure resolution. Systemic antifungals such as are reserved for severe, refractory, or immunocompromised cases, while adjunct measures include improving , managing underlying conditions like , and ensuring proper denture care to prevent recurrence. Early intervention is crucial to avoid complications such as esophageal extension or chronicity in at-risk patients.

Overview

Definition

Oral candidiasis is an of the oral cavity resulting from the overgrowth of Candida species, primarily , on the mucosal surfaces. This condition arises when the normal balance of oral microflora is disrupted, allowing commensal yeasts to proliferate excessively. It represents a common superficial mycosis, typically confined to the without deeper tissue invasion in most cases. The infection primarily affects the mouth but can extend to adjacent areas such as the oropharynx. Common sites of involvement include the , buccal mucosa (inner cheeks), hard and , and gingival tissues (). Historically, oral candidiasis has been referred to by various names, including thrush for the pseudomembranous form and moniliasis as an older synonym. The condition was first described in 1838 by pediatrician Francois Veilleaux.

Clinical importance

Oral candidiasis serves as a critical marker for underlying immunosuppression, frequently indicating compromised immune function in conditions such as , cancer, and . In HIV-positive individuals, it is the most common oral , affecting over 90% of patients and often correlating with low + T-cell counts. Similarly, it arises in patients undergoing for cancer or those with uncontrolled , where altered immune responses and local factors like facilitate fungal overgrowth. Increasingly, non-albicans Candida species and resistance are noted, complicating management as of 2024. This association underscores its value as an early sentinel for systemic health deterioration, prompting evaluation of predisposing conditions. The condition significantly impairs , leading to difficulties with eating, speaking, and maintaining due to symptoms such as burning sensations, oral bleeding, and altered taste. These disruptions can result in reduced nutritional intake, particularly in vulnerable populations, exacerbating and overall debility. In severe cases, progression to esophageal involvement may cause and , further limiting daily activities and social interactions. Oral candidiasis imposes a substantial economic burden on healthcare systems through recurrent infections and associated treatment costs, often necessitating prolonged therapy and management of resistance. In severe instances among immunocompromised patients, it is linked to systemic , with mortality rates of approximately 30-40% if occurs, as of 2024. Morbidity is particularly elevated in vulnerable groups, including infants (2-7%), the elderly (up to 75% in denture wearers), and immunocompromised individuals (>90% lifetime prevalence in and ~20% in cancer patients), where it contributes to chronic discomfort and heightened infection risk.

Classification

Pseudomembranous candidiasis

Pseudomembranous candidiasis, also known as thrush, manifests as creamy white or yellowish plaques that resemble curdled milk and can be easily removed from the affected mucosal surfaces. These pseudomembranes are composed of tangled fungal hyphae, desquamated epithelial cells, , inflammatory cells such as leukocytes, necrotic debris, and . The lesions most commonly appear on non-keratinized , including the buccal mucosa, dorsum of the , and , while they rarely involve keratinized tissues such as the attached gingiva or . A characteristic diagnostic feature is the scrape test, in which gentle removal of the pseudomembrane reveals an underlying erythematous and sometimes bleeding mucosal surface. This form of candidiasis shows a predilection for neonates and infants, as well as debilitated or chronically ill adults, such as the elderly or those with significant comorbidities. It is distinguished from other white oral lesions, such as , by the removability of the plaques, whereas leukoplakia presents as adherent, non-scrapable patches. Associated symptoms may include mild soreness or discomfort in the affected areas.

Erythematous candidiasis

Erythematous candidiasis, also referred to as atrophic candidiasis, manifests as diffuse or flat red patches on the , lacking the pseudomembranous plaques seen in other forms. This variant is characterized by its atrophic nature, featuring thinning of the and loss of filiform papillae, particularly on the dorsal surface of the , resulting in a smooth, reddened appearance. The condition commonly affects the dorsal tongue and the hard or , where the erythematous lesions may appear patchy or widespread. It can resemble due to the irregular red areas, but the presence of fungal elements, such as hyphae on microscopic examination, confirms the candidal . A key associated symptom is a burning sensation in the affected areas, often exacerbated by contact with spicy or acidic foods, contributing to discomfort during eating. This painful presentation aligns with broader subjective symptoms of oral candidiasis but is particularly prominent in erythematous forms. Erythematous candidiasis occurs in both acute and chronic forms; the acute type frequently develops following therapy, which disrupts normal oral flora, while the chronic form is prevalent among individuals with infection, where immune suppression allows persistent fungal overgrowth. Differentiation from conditions such as bacterial or allergic reactions relies on , which reveals characteristic Candida hyphae or spores in lesional scrapings, absent in those mimics.

Hyperplastic candidiasis

Hyperplastic candidiasis, also known as chronic hyperplastic candidiasis (CHC), is a subtype of oral characterized by persistent, adherent white plaques that do not scrape off easily, distinguishing it from pseudomembranous forms. These plaques typically appear as thick, homogeneous white lesions or speckled/nodular variants with multiple white nodules superimposed on an erythematous base, most commonly affecting the post-commissural buccal mucosa, , and . The hyperkeratotic underlying these lesions contributes to their firm, non-removable nature, often persisting for months or years due to ongoing Candida infection. This form predominates in adults, particularly those with a smoking or poor , which exacerbate the chronic inflammatory response and fungal persistence. , in particular, alters the oral environment to favor Candida overgrowth, increasing susceptibility to these hyperplastic changes. The condition's chronicity raises clinical concern due to its association with in over 15% of cases and a malignant transformation rate of approximately 12.1%, necessitating vigilant monitoring for potential progression to . Histopathological examination of hyperplastic candidiasis reveals candidal hyphae invading the superficial layers of the hyperplastic , accompanied by acanthosis and parakeratosis without deep tissue penetration. is essential not only to confirm the presence of fungal elements but also to assess for features, such as cellular changes in the speckled or nodular variants, which heighten the risk of malignant evolution. These findings underscore the importance of distinguishing CHC from other white lesions like , as the fungal component requires targeted antifungal intervention alongside .

Associated forms

Angular cheilitis, also known as perlèche, presents as fissured and erythematous lesions at the corners of the mouth, often involving candidal overgrowth, particularly , which contributes to the inflammatory process in susceptible individuals such as the elderly. This condition is characterized by cracking, , and sometimes secondary bacterial involvement, distinguishing it from isolated primary oral candidiasis forms by its perioral localization and multifocal potential when associated with systemic factors. Denture-related stomatitis refers to chronic inflammation of the mucosa underlying removable dentures, predominantly the , driven by candidal colonization in the presence of poor or ill-fitting appliances. It is classified according to Newton's system into three types: Type I features localized pinpoint hyperemia; Type II involves diffuse over the denture-bearing area; and Type III exhibits generalized across the entire affected mucosa. This form is appliance-related, differing from primary classifications by its mechanical predisposition and potential for multifocal extension beyond the oral cavity if untreated. Median rhomboid glossitis manifests as a well-demarcated, diamond-shaped erythematous patch on the central posterior dorsal , frequently linked to chronic Candida infection, though it may also represent a developmental anomaly with superimposed . The appears flat or slightly raised, red, and depapillated, often but occasionally contributing to subjective discomfort like burning, and it is histologically associated with atrophic and fungal hyphae. Unlike primary pseudomembranous or erythematous forms, it is site-specific to the midline and may involve kissing lesions on the from chronic contact. Linear gingival erythema is characterized by a distinct erythematous band along the marginal gingiva, particularly in individuals with infection, where it correlates with candidal overgrowth rather than typical plaque-induced . This condition presents as a 2-3 mm wide red line, often painless and non-bleeding on probing, and is considered a marker of immune compromise with Candida species implicated in its . It differs from broader primary by its localized gingival involvement and association with HIV-related . Chronic mucocutaneous candidiasis encompasses a rare syndrome of persistent, noninvasive Candida infections affecting the skin, nails, and mucous membranes, with oral manifestations including recurrent white plaques, fissures, and hyperplastic lesions in the perioral and intraoral regions. It typically onset in childhood due to genetic immune defects, leading to refractory oral involvement that may extend to angular cheilitis or . This form is distinguished from acute primary types by its chronic, multifocal nature and underlying immunological basis rather than transient risk factors. These associated forms of oral candidiasis are often multifocal or linked to specific anatomical or extrinsic factors like appliances, contrasting with the more uniform morphological presentations of primary classifications such as pseudomembranous or hyperplastic types.

Signs and symptoms

Subjective symptoms

Patients with oral candidiasis commonly report a burning sensation in the mouth, soreness, (difficulty or pain when swallowing), and (altered or loss of taste). These symptoms can vary in intensity, often described as a cottony feeling or general discomfort that affects the , cheeks, or . In some cases, patients note sensitivity to spicy or acidic foods due to heightened oral irritation, with loss of taste or painful swallowing more prominent in severe cases. Symptom presentation differs by form of the infection. Acute pseudomembranous may cause sudden burning or soreness, though it is often in mild cases. Erythematous typically involves more pronounced burning and sore mouth sensations. In contrast, hyperplastic tends to produce chronic, low-level discomfort or remain entirely . infections are particularly common in early or mild presentations across various types, where patients may not notice any issues until progression. These subjective experiences can significantly impair daily activities, leading to aversion to certain foods and reduced intake, which in severe cases with esophageal involvement may contribute to . Patient histories often include details on symptom onset, which may be gradual or acute, duration ranging from days to months, and exacerbating factors such as discomfort worsening with denture wear.

Objective findings

Objective findings in oral candidiasis are identified through clinical examination and include characteristic visual and tactile abnormalities in the oral cavity. Visual inspection often reveals creamy white patches or lesions resembling cottage cheese that are adherent to the mucosal surfaces, such as the tongue, inner cheeks, gums, tonsils, throat, or roof of the mouth; these plaques can be scraped off, sometimes causing slight bleeding, exposing an underlying erythematous base. Similar white residue may appear on the lips, which is typically not concerning unless presenting as thick, cottage-cheese-like patches that do not wipe off easily, persist throughout the day, and are associated with soreness or redness, potentially indicating oral candidiasis. Erythema may appear as diffuse red patches, particularly on the dorsal tongue or palate, sometimes accompanied by fissuring or mucosal atrophy with loss of filiform papillae. In affected areas, atrophy can manifest as smooth, shiny mucosal surfaces due to epithelial thinning, often with accompanying redness or soreness. Palpation during examination may detect tenderness in inflamed regions, especially in acute presentations, while chronic forms like hyperplastic lesions can present with induration or firm, raised plaques that do not scrape away. These tactile findings often align with patient complaints of upon touch or eating. Extraoral signs include , characterized by cracking, fissuring, or crusting at the corners of the mouth, which may involve secondary bacterial overgrowth such as . In immunocompromised individuals, progression patterns may show spread of lesions to the pharynx, with extension of erythema or plaques leading to visible involvement of the posterior oral cavity.

Pathophysiology

Causative organisms

Oral candidiasis is primarily caused by fungi of the genus Candida, with Candida albicans being the predominant species responsible for 70-80% of cases. This dimorphic yeast can exist in both unicellular yeast forms and invasive hyphal (filamentous) forms, which contribute to its pathogenicity in the oral environment. Other Candida species, including C. glabrata, C. tropicalis, C. krusei, and C. parapsilosis, account for the remaining cases and are increasingly implicated in infections, particularly non-albicans species that exhibit higher rates of resistance. These non-albicans Candida species are emerging as significant pathogens in oral candidiasis due to their intrinsic or acquired resistance to common azole antifungals like . Candida species are typically commensal components of the normal oral flora, colonizing the mouths of 30-60% of healthy individuals without causing disease. Under certain conditions, this commensal population can overgrow and shift to an opportunistic pathogenic state, leading to infection. Key virulence factors of C. albicans and related species include adhesins such as agglutinin-like sequence (ALS) proteins, which facilitate attachment to host epithelial cells; secreted aspartyl proteinases (Saps) that degrade host tissues and immune factors; and phospholipases that disrupt cell membranes to aid invasion. These factors enable the fungus to adhere, invade, and evade host defenses in the oral mucosa. Speciation of Candida isolates from oral lesions is often achieved using chromogenic media like CHROMagar Candida, which allows presumptive identification based on colony color and morphology (e.g., green for C. albicans, pink for C. glabrata).

Infection mechanisms

Candida albicans, the primary causative organism of oral candidiasis, typically exists as a commensal in the oral cavity but transitions to a pathogen through dimorphic switching from yeast to hyphal forms, triggered by environmental cues such as elevated temperature, neutral pH, and nutrient availability like serum or N-acetylglucosamine. This morphological shift is essential for virulence, as hyphae exhibit directional growth via thigmotropism, allowing penetration of oral epithelial surfaces. Adherence to oral epithelial cells is facilitated by hyphal formation and the expression of adhesins such as Als3 and Hwp1, which bind to host receptors like E-cadherin, promoting close contact and colonization. Biofilm production further enhances adherence, with yeast cells initially attaching to surfaces before proliferating into a mixed hyphal-yeast community embedded in an extracellular polysaccharide matrix, particularly in denture-related cases where biofilms on acrylic surfaces serve as reservoirs for persistent infection. Invasion follows, driven by secreted enzymes including aspartyl proteinases (Saps, such as Sap1-3) and phospholipases, which degrade epithelial tight junctions, basement membranes, and mucosal barriers to enable deeper tissue penetration. Immune evasion mechanisms include inhibition of phagocytosis, achieved through hyphal elongation that allows escape from neutrophil engulfment and masking of cell wall chitin to reduce recognition by host pattern recognition receptors. A key virulence factor is candidalysin, a pore-forming peptide toxin produced by hyphae from the Ece1 gene, which lyses epithelial cells, induces DNA damage, and disrupts barrier integrity while suppressing protective immune responses. This toxin also elicits an inflammatory response by activating epithelial signaling pathways that recruit neutrophils via cytokines like IL-17 and IL-22 from Th17 cells, contributing to tissue erythema and pseudomembrane formation through neutrophil extracellular traps and reactive oxygen species, though biofilms confer resistance to these defenses. In denture-associated infections, the biofilm matrix shields embedded fungi from neutrophil killing and antifungal agents, perpetuating the infection cycle.

Risk factors

Local factors

Local factors contributing to the development of oral candidiasis primarily involve alterations in the oral environment and modifiable behaviors that favor Candida overgrowth. These include disruptions to salivary protection, mechanical irritation, and conditions that provide nutritional support for proliferation within the . Unlike systemic influences, local factors are often directly addressable through oral care practices and lifestyle adjustments. Xerostomia, or dry mouth, significantly increases the risk of oral candidiasis by reducing saliva flow, which normally inhibits fungal growth through its antifungal components such as histatins and . This condition can arise from medications like anticholinergics or antihistamines, or from head and neck , leading to diminished clearance of oral microbes and a more hospitable environment for Candida adhesion and formation. Studies have shown that individuals with exhibit higher rates of Candida colonization compared to those with normal salivary function. Denture wearing is a prominent local , particularly when are ill-fitting, worn continuously overnight, or inadequately cleaned, as these promote accumulation on both the and underlying mucosa. Poorly maintained create microenvironments with trapped moisture and debris, facilitating Candida adherence and the development of denture , a common manifestation of oral candidiasis. Research indicates that continuous denture use without removal at night significantly increases the risk of candidal infection in wearers. Tobacco smoking alters the oral mucosa's and enhances keratinization, creating conditions that particularly favor the hyperplastic form of by reducing epithelial shedding and promoting fungal persistence. Cigarette smoke components irritate the mucosa and may provide nutrients that support Candida growth, with smokers demonstrating significantly higher carriage rates of compared to non-smokers. This local effect is compounded by smoking's drying influence on the oral cavity, further impairing natural defenses. Poor contributes to plaque accumulation, which supplies carbohydrates and other nutrients that fuel Candida proliferation in the oral . Inadequate brushing, flossing, or denture cleaning allows for the buildup of microbial communities where Candida thrives, increasing risk in both edentulous and dentate individuals. Clinical observations link suboptimal practices to elevated fungal loads and symptomatic candidiasis. High intake of dietary sugars and carbohydrates promotes growth by elevating glucose levels in , providing an ideal substrate for Candida metabolism and adhesion to oral surfaces. Unbalanced consumption of refined sugars has been associated with increased candidal , as these simple carbohydrates enhance fungal without the buffering effects of a varied diet. Experimental models confirm that carbohydrate-rich diets accelerate Candida formation . Mucosal trauma from ill-fitting dental appliances, aggressive brushing, or habitual cheek biting disrupts the integrity of the oral epithelium, allowing Candida to invade compromised tissues more readily. Such injuries create entry points for fungal hyphae and reduce local immune surveillance, with denture-related trauma a common factor implicated in many cases of denture involving . Healing delays in traumatized areas further perpetuate infection risk.

Systemic factors

Systemic factors play a crucial role in predisposing individuals to oral candidiasis by altering host immunity, mucosal integrity, or the oral microenvironment in ways that favor Candida overgrowth. These include conditions and therapies that affect the body globally, distinct from local oral influences. Key examples encompass immunodeficiencies, endocrine imbalances, certain medications, nutritional deficits, age-related vulnerabilities, and hormonal fluctuations. Immunodeficiencies significantly increase susceptibility to oral candidiasis, particularly through suppression of T-cell mediated immunity. In patients, oral candidiasis occurs in over 90% of cases, often serving as an early indicator when + T-lymphocyte counts fall below 200 cells/mm³. for malignancies and immunosuppressive regimens following organ transplants similarly impair T-cell function, leading to higher Candida colonization rates, with up to 95% in HIV-positive individuals and high rates (up to 90% in some cases) in patients undergoing for hematologic malignancies, including . Endocrine disorders, notably uncontrolled diabetes mellitus, promote fungal proliferation via , which provides an enriched nutrient source for Candida species in and mucosal tissues. Elevated glucose levels in diabetics foster an alkaline oral environment conducive to candidal adhesion and growth. Broad-spectrum antibiotics and systemic corticosteroids are major iatrogenic risk factors. Antibiotics, particularly broad-spectrum or prolonged courses, disrupt the normal oral , reducing bacterial competition and allowing Candida dominance, which can lead to oral candidiasis such as acute atrophic or erythematous forms. This is uncommon with short courses, such as azithromycin treatment for dental infections in immunocompetent patients. Routine prophylactic antifungal therapy is not recommended in such cases unless additional high-risk factors are present (e.g., immunosuppression or prolonged antibiotic use). Corticosteroids, by suppressing immune responses including and macrophage activity, further impair clearance of fungal elements. Nutritional deficiencies contribute by causing mucosal atrophy and weakened local defenses. Deficiencies in iron, , or lead to atrophic , increasing vulnerability to infection; for instance, up to 85% of patients with exhibit oral candidiasis signs like . Extremes of age heighten risk due to immune immaturity or decline. Neonates face elevated susceptibility during the first month of life owing to underdeveloped immune systems, with Candida carriage rates around 45%. In the elderly, multifactorial immune combined with comorbidities results in carriage rates of 65-88%, particularly in institutionalized settings. Hormonal changes, such as those in or from oral contraceptives, alter the to favor Candida colonization. induces glycogen overproduction in mucosal cells, creating an alkaline environment that supports fungal growth, with pregnant women showing higher oral carriage than non-pregnant counterparts. Oral contraceptives containing similarly promote Candida albicans colonization in the oral cavity by estrogen-mediated changes in mucosal flora and immunity.

Diagnosis

Clinical assessment

The clinical assessment of oral candidiasis begins with a thorough history taking to identify symptom duration, such as the onset and persistence of oral discomfort, burning sensation, or altered taste, which typically develop over days to weeks. Clinicians inquire about recent use of antibiotics, corticosteroids, or immunosuppressive therapies, as well as underlying medical conditions like , , or that may predispose to infection. Additional details on denture wear, nutritional status, and history are elicited to assess local and systemic risk factors. Physical examination involves systematic intraoral inspection under adequate lighting and magnification to evaluate lesion distribution across the buccal mucosa, , , and floor of the mouth. Characteristics such as removable white pseudomembranes, erythematous patches, or adherent plaques are noted for their texture, color, and response to gentle scraping, aiding in . The extraoral examination includes palpation of the perioral skin and commissures to detect , characterized by fissuring and , or extension to adjacent cutaneous areas in immunocompromised patients. Differential diagnosis relies on clinical pattern recognition to distinguish oral candidiasis from conditions like , which presents with lacy white lines and bilateral involvement, featuring homogeneous white patches without removability, or viral ulcers showing punched-out borders and clustered vesicles. Suspicious hyperplastic areas, which may mimic premalignant lesions, warrant vital staining with toluidine blue to highlight dysplastic changes, guiding further evaluation if uptake occurs.

Confirmatory tests

Confirmatory tests for oral candidiasis provide objective laboratory evidence to verify the presence of Candida species and distinguish it from clinical mimics, following initial suspicion from clinical assessment. These tests are particularly essential in immunocompromised patients or cases of recurrent or atypical presentations, where speciation and antifungal susceptibility can guide management. Common methods include , culture, cytology, , , and sensitivity testing, each offering varying degrees of specificity and turnaround time. Microscopy remains a rapid, first-line confirmatory approach, utilizing potassium hydroxide (KOH) preparation or Gram staining of oral scrapings to reveal characteristic budding yeast forms and pseudohyphae. In KOH prep, the alkali dissolves keratin and epithelial debris, allowing visualization of fungal elements under light microscopy, with pseudohyphae appearing as elongated, branching structures indicative of Candida infection. Gram staining typically shows Gram-positive yeasts and filaments, with reported sensitivities of 30-70% in oral samples, confirming the diagnosis rapidly in many straightforward cases within minutes. This method's simplicity makes it accessible in clinical settings, though it lacks species identification. Culture on selective media, such as Sabouraud dextrose , is the gold standard for isolating and confirming Candida growth from oral swabs or scrapings, typically yielding visible colonies within 24-48 hours at 35-37°C. follows via biochemical tests (e.g., carbohydrate assimilation profiles using API 20C AUX system) or (MALDI-TOF MS), which provides rapid, accurate identification of species like C. albicans or non-albicans types with >95% accuracy. Culture is crucial for quantifying fungal burden and detecting mixed infections but requires 2-5 days for full results. Cytological examination involves Papanicolaou (PAP), periodic acid-Schiff (), or Gomori methenamine silver (GMS) staining of exfoliative cytology smears to detect invasive hyphae within epithelial tissue, particularly useful in chronic hyperplastic . PAS highlights fungal cell walls in magenta, while GMS stains them black against a green background, improving detection sensitivity to 90% in tissue samples. These stains differentiate superficial from invasive disease and are often performed on brush biopsies for non-invasive sampling. Molecular tests, such as (PCR) assays targeting Candida-specific DNA sequences (e.g., ITS region or 18S rRNA), enable rapid detection directly from oral swabs, with results in 2-4 hours and sensitivity exceeding 95% for both albicans and non-albicans species. Real-time PCR multiplex panels can simultaneously identify multiple Candida species and resistance markers, proving valuable in azole-refractory cases involving C. glabrata or C. krusei. These methods are increasingly adopted in high-risk settings for their speed and ability to detect low fungal loads. As of 2025, real-time PCR and MALDI-TOF MS are increasingly used for rapid detection and in high-risk cases, including emerging pathogens like C. auris. Biopsy with histopathological examination is indicated for persistent or hyperplastic lesions to confirm and rule out premalignant changes like , using fungal-specific stains such as PAS or GMS on tissue sections. reveals parakeratosis, acanthosis, and intraepithelial hyphae or spores, with GMS enhancing visibility of invasive forms. This invasive procedure, often with or incisional technique, is reserved for atypical presentations due to its 100% specificity when positive. Antifungal susceptibility testing, performed via or on cultured isolates per Clinical and Laboratory Standards Institute (CLSI) guidelines, identifies resistance patterns, such as resistance in C. glabrata (MIC >64 μg/mL) or resistance in C. auris. This is critical for guiding therapy in recurrent infections, with resistance rates variable (up to 30% in some data for certain non-albicans ). Testing turnaround is 24-48 hours post-culture and is recommended for all non-responsive cases.

Treatment

Supportive measures

Supportive measures for oral candidiasis focus on alleviating symptoms, promoting , and preventing recurrence through non-pharmacological interventions that enhance oral comfort and . These approaches are particularly beneficial in mild cases, where they can facilitate resolution without additional therapies, and serve as adjuncts in more severe presentations by reducing irritation and supporting the oral environment. Maintaining rigorous is a of supportive care. Patients are advised to use a soft-bristled for gentle brushing twice daily to avoid further trauma to inflamed mucosa, combined with daily flossing to remove plaque and debris that may harbor Candida species. Antiseptic rinses, such as 0.12% gluconate, can be used as mouthwashes (typically 10-15 mL swished for 30 seconds twice daily) to reduce microbial load and inhibit fungal adhesion, though prolonged use should be monitored to prevent side effects like . Avoiding irritants such as , alcohol, and spicy or abrasive foods helps minimize mucosal disruption and supports recovery. For denture wearers, who are at elevated risk due to potential microbial reservoirs on prostheses, specific management is essential. should be removed nightly and soaked in an solution, such as diluted or hypochlorite-based cleansers, to eradicate adherent Candida biofilms; daily mechanical cleaning with a soft brush and non-abrasive paste is also recommended. If ill-fitting contribute to chronic irritation, professional refitting by a ensures proper adaptation and reduces stagnation areas prone to . These steps alone can resolve denture-related in some cases by disrupting the fungal habitat. Dietary modifications aid in symptom relief by reducing oral discomfort and addressing contributing factors like . Consuming soft, non-acidic foods—such as mashed vegetables, , and soups—minimizes irritation to lesional areas, while avoiding sugary or yeasted items limits substrate for fungal growth. Adequate hydration is crucial, with frequent sips of encouraged to combat dry mouth, which exacerbates candidal proliferation; warm saltwater rinses (1/2 teaspoon salt in 8 ounces of , swished and spit several times daily) can soothe inflammation and promote salivation. Symptomatic pain relief can be achieved with over-the-counter topical anesthetics applied directly to affected areas. Gels containing 20% , used sparingly 3-4 times daily, provide temporary numbing to ease eating and speaking, particularly in erosive or pseudomembranous forms; application should follow to ensure efficacy. Patients with concurrent benefit from saliva substitutes like carboxymethylcellulose-based products (e.g., oral rinse or gel, applied as needed), which lubricate the mucosa, reduce friction, and help maintain a moist environment less conducive to Candida overgrowth. In mild oral candidiasis, close follow-up involves monitoring symptoms weekly through clinical reassessment, with resolution often observed within 7-14 days via and supportive practices alone. Persistent or worsening signs necessitate reevaluation to rule out complications or resistance, emphasizing the role of these measures in empowering self-management while bridging to further interventions if required.

Antifungal therapies

Antifungal therapies form the cornerstone of treatment for oral candidiasis, targeting the overgrowth of Candida species, primarily C. albicans, in the oral mucosa. These therapies are selected based on the severity of the infection, patient factors such as immune status, and potential for resistance. Topical agents are preferred for uncomplicated, mild cases due to their localized action and lower risk of systemic side effects, while systemic options are reserved for moderate to severe, recurrent, or refractory infections. For mild cases, topical polyenes and azoles are first-line treatments. Nystatin suspension (100,000 units/mL, 4–6 mL swished and swallowed four times daily) or pastilles (200,000 units each, one to two four times daily) for 7–14 days is recommended, with strong evidence supporting its in resolving symptoms without promoting widespread resistance. Clotrimazole troches (10 mg dissolved slowly five times daily for 7–14 days) are similarly effective, particularly for denture , where they achieve high local concentrations to eradicate adherent Candida biofilms on prosthetic surfaces. Miconazole mucoadhesive buccal tablets (50 mg once daily applied to the gum for 7–14 days) offer an alternative for localized , with comparable outcomes in clinical trials. In moderate to severe or recurrent cases, systemic azoles are indicated to ensure adequate penetration and broader coverage. Oral (100–200 mg daily for 7–14 days) is the preferred agent, demonstrating high cure rates in immunocompromised patients and those with extensive involvement, supported by randomized controlled trials. For fluconazole-resistant strains, alternatives include oral solution (200 mg daily for up to 28 days), which maintains activity against many azole-resistant isolates. Other options like suspension (400 mg twice daily for three days, then 400 mg daily for up to 25 days) or (200 mg twice daily for 14–21 days) are used in refractory scenarios, with monitoring for drug interactions due to CYP450 . For azole-resistant infections, polyene antifungals provide a non-azole alternative. deoxycholate oral suspension (100 mg/mL, 1 mL four times daily) is effective against resistant Candida species, binding to in fungal membranes to disrupt cell integrity, though its bitter taste may limit adherence. Echinocandins, such as (70 mg intravenous loading dose followed by 50 mg daily), (100 mg intravenous daily), or (200 mg intravenous loading dose followed by 100 mg daily), are considered for cases with invasive extension beyond the oral cavity, though their use in isolated oral candidiasis is rare and typically reserved for hospitalized patients with poor response to oral therapies. For azole-resistant or refractory cases, emerging oral options like (300 mg twice daily for one day) may be considered, as per recent guidelines. Treatment duration is generally 7–14 days for initial , extended to 21–28 days in cases, with clinical response guiding to topical agents or discontinuation to minimize resistance development. Monitoring involves weekly clinical assessment for resolution and confirmation if resistance is suspected, alongside for systemic azoles to detect rare . In recurrent cases, chronic suppressive with (100 mg three times weekly) may be employed after addressing predisposing factors.

Addressing underlying causes

Managing underlying causes of oral candidiasis is essential to prevent recurrence, as the infection often arises from predisposing factors that compromise oral mucosal defenses. In patients with , such as those with , optimizing antiretroviral therapy () restores + T-cell counts and reduces the incidence of opportunistic infections like oral candidiasis, which affects up to 90% of untreated patients. Similarly, for individuals undergoing , adjusting immunosuppressive regimens where feasible, in consultation with oncologists, can mitigate infection risk by improving immune function. For patients with , achieving glycemic control through medical management and lifestyle modifications lowers salivary glucose levels, thereby decreasing Candida colonization and the prevalence of oral candidiasis, which is significantly higher in those with poor glycemic control ( 13.0 for HbA1c >12%) and in denture wearers ( 4.78). A comprehensive medication review is also critical; broad-spectrum antibiotics should be discontinued or switched when possible, as their use disrupts normal oral flora and promotes candidal overgrowth, often resolving the infection upon cessation. Likewise, tapering corticosteroids or instructing patients to rinse their mouth with water after use reduces local and fungal adhesion. Denture optimization plays a key role in edentulous patients, where ill-fitting prostheses cause mucosal trauma and accumulation. Professional dental evaluation for adjustments ensures proper fit, while expert cleaning removes embedded yeasts more effectively than home methods, reducing recurrence rates in denture cases. programs, including counseling and , are recommended, as tobacco use increases epithelial keratinization and salivary flow reduction, elevating candidal carriage; quitting has been shown to aid resolution of chronic forms like hyperplastic candidiasis. Finally, nutritional supplementation targets identified deficiencies via blood tests, such as iron, , , or , which impair mucosal immunity and are linked to higher risk, particularly in or HIV-associated cases; correcting these enhances host defenses and prevents relapse.

Prognosis and prevention

Prognosis

In healthy individuals, oral candidiasis typically resolves within 1 to 2 weeks following appropriate treatment and supportive measures, such as improved . However, the condition is often recurrent in immunocompromised patients, with relapse rates reaching up to 80% in those with AIDS if underlying factors like low CD4 counts are not controlled. Poor prognostic indicators include infections caused by non-albicans Candida species, which exhibit higher antifungal resistance; the presence of biofilms, which confer tolerance to therapies and promote persistence; and patient non-compliance with treatment regimens. Mortality from oral candidiasis is rare in most cases but can be substantial in vulnerable populations, such as preterm infants where disseminated carries a 25% to 35% fatality rate. The hyperplastic form of oral candidiasis, if left untreated, may progress to oral in approximately 5% to 12% of cases due to chronic inflammation and . Early diagnosis and prompt intervention significantly enhance recovery rates and reduce complications in affected individuals.

Prevention strategies

Maintaining rigorous is essential for preventing oral candidiasis. Regular brushing twice daily with a soft and , combined with daily flossing and mouth rinses, reduces the buildup of plaque and overgrowth in the . dental cleanings every six months further minimize risk by removing tartar and addressing early signs of . In high-risk populations, such as immunocompromised patients undergoing or , prophylactic therapy with low-dose (typically 100-200 mg daily) is recommended to suppress Candida colonization and prevent invasive disease. This approach has demonstrated efficacy in reducing recurrence rates, though it should be used judiciously to avoid promoting resistance. For denture wearers, who are particularly susceptible due to potential microbial harboring on prosthetic surfaces, specific protocols are critical. Daily disinfection of using effervescent cleansers or dilute solutions, followed by thorough rinsing and air drying, significantly lowers adherence. Avoiding overnight wear allows mucosal recovery and reduces inflammation, with evidence showing resolution of denture-related in up to two weeks when combined with practices. Lifestyle modifications play a supportive role in prevention. A balanced diet low in refined sugars limits substrate for proliferation, while quitting decreases oral irritation and immune suppression that favor candidal overgrowth. Adequate hydration and avoiding excessive alcohol further promote a healthy oral . Research into offers promising long-term prevention for . The NDV-3A , targeting the Candida adhesin Als3p, has shown and efficacy against recurrent vulvovaginal in phase II trials, with reduced recurrence rates in affected women as of data up to 2025. Preclinical studies suggest potential protection against oral mucosal infections, and ongoing research aims to evaluate its application for oral . In healthcare settings like neonatal intensive care units (NICUs), where nosocomial transmission of Candida can occur, strict hand protocols are paramount. Alcohol-based sanitizers applied before and after patient contact have been shown to reduce fungal transmission rates by over 50% in these vulnerable environments. Isolation of colonized infants and environmental cleaning further mitigate spread.

Epidemiology

Prevalence and incidence

Oral candidiasis, also known as oral thrush, exhibits varying and incidence rates globally, influenced by factors such as asymptomatic and clinical manifestations. In the general population, asymptomatic carriage of Candida species in the oral cavity ranges from 20% to 80%, with being the predominant species in up to 70% of healthy individuals. Clinical disease, however, is less common, with an estimated annual incidence of approximately 8 cases per 100,000 people, though transient episodes may occur in a significant portion of healthy adults over their lifetime due to opportunistic overgrowth. Incidence rates are notably higher in specific at-risk scenarios, such as among elderly denture wearers, where denture —a form of oral —affects 20% to 67% of individuals, with rates reaching 78%. Annual incidence in this group is estimated at 1% to 3%, driven by factors like poor denture and reduced salivary flow. In individuals with untreated (pre-antiretroviral therapy), prevalence of symptomatic oropharyngeal ranges from 20% to 50%, particularly in those with low counts, underscoring its role as an early . Recent trends indicate a shift toward non-albicans Candida species, such as C. glabrata and C. tropicalis, comprising up to 30-50% of isolates in some settings, largely attributable to widespread use and emerging resistance, with resistance rates exceeding 10% in non-albicans strains. The (2020-2023) contributed to a rise in hospitalized cases, with incidence rates of 10-17% among critically ill patients, linked to immune dysregulation, prolonged ventilation, and use. Geographic variations highlight higher prevalence in tropical climates compared to temperate regions; for instance, rates in range from 10-44% in certain cohorts, versus 2-5% in European populations, influenced by environmental , socioeconomic factors, and differences in Candida , with C. tropicalis more common in tropical areas. Underreporting is substantial due to or mild cases, which skew epidemiological data, as routine screening is not standard and many colonizations resolve without medical attention.

Affected populations

Oral candidiasis disproportionately affects certain demographic and clinical groups, with incidence and varying based on age, immune status, and comorbidities. Neonates and infants represent a key vulnerable , particularly those born preterm, due to immature immune defenses and potential from maternal vaginal . In healthy newborns, thrush—the most common form of oral candidiasis—affects approximately 2-5%, with rates increasing to around 14% by the fourth week of life as oral peaks before immunity strengthens after six months. Preterm infants face even higher risks, with rates up to 23.5% and progression to symptomatic infection more likely in those with ≤30 weeks. Among older adults, the elderly are particularly susceptible, especially denture wearers, where multifactorial elements like reduced salivary flow, poor , and comorbidities contribute to higher rates. Prevalence among institutionalized or hospitalized elderly ranges from 13% to 47%, with denture-related forms such as affecting 20-40% of this subgroup, and rates climbing to over 33% in those aged 80 and above. Immunocompromised individuals experience the highest burden, with oral candidiasis serving as an early indicator of immune decline. In patients with advanced , lifetime prevalence exceeds 90%, though rates of 50-90% are common in untreated or late-stage cases before antiretroviral therapy. Similarly, among patients undergoing , incidence ranges from 6% to 53%, often approaching 50% or higher in those with severe . Patients with diabetes mellitus also face elevated risks, particularly when glycemic control is poor, as promotes fungal adhesion and proliferation in the oral cavity. of oral candidiasis in this group is approximately 20-30%, representing a 2-3-fold increase compared to non-diabetics, with uncontrolled cases showing carriage rates up to 90%. Demographic patterns reveal peaks in infancy and advanced age, with overall incidence bimodal across the lifespan. Some studies in specific subgroups, such as denture wearers, report a slight predominance, potentially linked to higher denture use. Socioeconomic disparities exacerbate vulnerability, as low-resource settings with poor and correlate with 4.5-5.3 times higher rates, particularly among infants and underserved adults.

History

Early recognition

Oral candidiasis, commonly known as thrush, has been recognized in for millennia, with initial descriptions focusing on its characteristic white oral lesions. The earliest documented account dates back to , where (c. 460–370 BCE) described cases of "aphthae" as painful white sores or ulcerations in the mouth, often associated with severe underlying illnesses such as fever or wasting diseases, terming it a "disease of the diseased." These observations, recorded in his work Of the Epidemics, likely referred to pseudomembranous oral candidiasis, though the fungal was unknown at the time. The colloquial name "thrush" emerged in English medical terminology by the 17th century, drawing an analogy between the creamy white patches of the infection and the white breast feathers of the thrush bird (Turdus species). This descriptive term, first appearing in records around 1665, highlighted the visible pseudomembranes formed by fungal hyphae, desquamated epithelial cells, and inflammatory cells, aiding in its clinical identification long before microbiological confirmation. Significant progress in understanding the condition's occurred in the , as revealed its nature. In 1839, German pathologist Bernhard von Langenbeck first identified a yeast-like in the oral scrapings of a patient with thrush, describing it as a "cryptogamic plant" and noting its role in the lesions, marking the initial link between and human oral disease. This observation was expanded in 1846 by Danish physician Jacob Christian Berg, who confirmed thrush as a through microscopic examination. Seven years later, French mycologist Charles Philippe Robin classified the organism as Oidium albicans, derived from the Latin for "egg white" due to its whitening effect on tissues. The modern taxonomic foundation was established in the early . In 1923, Dutch mycologist Christine Marie Berkhout proposed the genus Candida to encompass various yeast-like fungi, including the primary pathogen , named after the Latin "toga candida" (white ) to reflect the opaque white appearance of its colonies on culture media. This reclassification resolved prior nomenclatural confusion and solidified C. albicans as the key agent in oral candidiasis.

Key developments

In the mid-20th century, the discovery of polyene antifungals marked a pivotal advance in treating oral candidiasis. Nystatin, isolated in 1950 from noursei by Elizabeth Lee Hazen and Rachel Fuller Brown, became the first effective antifungal agent safe for human use, particularly for topical and oral applications against Candida infections such as thrush. , discovered in 1955 from nodosus, emerged as the first systemic antifungal, offering broader efficacy against , though its use was limited by toxicity for oral lesions. The 1980s brought heightened recognition of oral candidiasis as a key in the emerging epidemic, serving as an early clinical indicator of even before formal AIDS-defining criteria were established in 1987. This period also saw the introduction of azole antifungals, with patented in 1981 following a development program initiated in 1978, revolutionizing treatment through its oral bioavailability and efficacy against mucosal candidiasis in immunocompromised patients. During the 2000s, research illuminated the role of Candida biofilms in persistent oral infections, revealing their resistance to antifungals and association with devices like , which complicated management. Concurrently, the rise of non-albicans Candida species, such as C. glabrata and C. krusei, was documented, driven by selective pressure and linked to increased resistance in settings. Advancements in the 2010s focused on and . (PCR)-based assays enabled rapid species identification and resistance profiling from oral swabs, improving diagnostic accuracy over culture methods. In , candidalysin was identified as a cytolytic toxin from hyphal C. albicans, essential for epithelial damage in and a potential therapeutic target. Recent developments in the 2020s include novel antifungals and preventive strategies. Rezafungin, a long-acting , received FDA approval in March 2023 for candidemia and , offering once-weekly dosing to address resistance challenges. candidates, such as NDV-3A targeting adhesins like Als3p, advanced to phase II trials by the early 2020s, demonstrating immunogenicity against mucosal candidiasis including oral forms in preclinical models. In 2025, the Global Guideline for the Diagnosis and Management of was published, providing updated recommendations for managing various forms of candidiasis, including oral manifestations.

Society and culture

Public perceptions

Oral candidiasis, commonly known as thrush, carries significant stigma among immunocompromised individuals, particularly those with , where it is frequently associated with the disease and leads to embarrassment in seeking dental care. Studies indicate that HIV-related stigma in dental settings discourages people living with (PLWHA) from accessing oral health services, with 43% reporting hesitation due to fears of judgment or breaches of , resulting in untreated conditions like . This stigma exacerbates unmet oral health needs, as up to 58% of PLWHA forgo necessary dental visits, delaying treatment for opportunistic infections such as thrush. Candida species are normal oral flora that overgrow under specific conditions, such as immune suppression or use, affecting even those with good practices. This view overlooks the infection's role as a marker of underlying vulnerabilities, such as in or . Post-AIDS era awareness campaigns by organizations like the WHO and CDC have aimed to destigmatize -related conditions, including oral manifestations like , by promoting education and reducing fear. The CDC's "Let's Stop HIV Together" initiative, launched in 2012, highlights personal stories to combat stigma and encourage open discussions about , indirectly addressing barriers to care for associated infections such as thrush in vulnerable populations. These efforts emphasize tolerance and accurate information to improve health-seeking behaviors among affected groups. Access to diagnosis remains challenging in low-income groups, where underdiagnosis of oral candidiasis stems from limited and health disparities, leading to higher untreated rates among racial/ethnic minorities and uninsured individuals. Low awareness contributes to delayed care, with socioeconomic barriers exacerbating the prevalence of fungal infections in these populations.

Cultural references

Oral candidiasis, commonly known as thrush, features prominently in traditions across various regions, where it is often attributed to causes and treated through ritualistic practices. In from the 19th and early 20th centuries, thrush in infants was believed to be curable by individuals who had never seen their fathers; these "thrush doctors" would blow their breath into the child's mouth three times to dispel the affliction, a practice documented in rural accounts from counties like Leitrim. Similarly, in Appalachian folk medicine of the American South, women would travel long distances, often on horseback, to seek out such healers who could blow away the "thrash" or mouth sores afflicting babies, reflecting a cultural belief in inherited or innate curative powers. Gentian violet, a synthetic introduced in the late , became a staple in traditional remedies for thrush due to its properties, applied topically to the mouth in both Western and some non-Western households as a low-cost, accessible treatment passed down through generations. In non-Western contexts, such practices extend to ethnobotanical traditions; for instance, among the of , various plants are prepared as decoctions or poultices to manage oral fungal infections, emphasizing communal knowledge of local for care. In Asian folklore and , herbs such as (black seed) and (henna) are invoked in remedies for oral candidiasis, often blended into pastes or oils and referenced in oral histories as protective against childhood ailments. These cultural depictions highlight thrush not merely as a medical condition but as a communal concern intertwined with stigma around , where remedies blend empirical with mystical elements to restore health.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.